Abstract
Rational drug design utilizing a receptor homology model of the human muscarinic M1 receptor led to the discovery of the highly potent (Ki = 2 nM), efficacious, and in vivo functionally-selective M1 agonist, WAY-132983.
MeSH terms
-
Administration, Oral
-
Animals
-
Bridged-Ring Compounds / chemistry*
-
Bridged-Ring Compounds / pharmacology*
-
CHO Cells / metabolism
-
Carbachol / chemistry
-
Carbachol / metabolism
-
Carbachol / pharmacology
-
Cerebral Cortex / metabolism
-
Cognition Disorders / drug therapy
-
Computer Simulation
-
Cricetinae
-
Crystallography, X-Ray
-
Drug Design
-
Drug Evaluation, Preclinical
-
Humans
-
Macaca mulatta
-
Maze Learning / drug effects
-
Models, Molecular
-
Muscarinic Agonists / chemistry*
-
Muscarinic Agonists / pharmacology*
-
Phosphatidylinositols / metabolism
-
Protein Conformation
-
Pyrazines / chemistry*
-
Pyrazines / pharmacology*
-
Pyridines / chemistry
-
Pyridines / pharmacology
-
Rats
-
Receptor, Muscarinic M1
-
Receptors, Muscarinic / chemistry
-
Receptors, Muscarinic / metabolism*
-
Salivation / drug effects
-
Structure-Activity Relationship
-
Thiadiazoles / chemistry
-
Thiadiazoles / pharmacology
Substances
-
Bridged-Ring Compounds
-
Muscarinic Agonists
-
Phosphatidylinositols
-
Pyrazines
-
Pyridines
-
Receptor, Muscarinic M1
-
Receptors, Muscarinic
-
Thiadiazoles
-
WAY 132983
-
Carbachol
-
xanomeline